The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Detalhes bibliográficos
Autor(a) principal: Eisig,Jaime Natan
Data de Publicação: 2003
Outros Autores: André,Suraia Boaventura, Silva,Fernando Marcuz, Hashimoto,Cláudio, Moraes-Filho,Joaquim Prado Pinto, Laudanna,Antonio Atilio
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Arquivos de gastroenterologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000100012
Resumo: BACKGROUND: Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. AIM: We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. METHODS: Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. RESULTS: One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/15 (67%)]. There were six (15%) mild adverse events reports. CONCLUSIONS: A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.
id IBEPEGE-1_a027d7cd1198c702a6c5614ae88ce863
oai_identifier_str oai:scielo:S0004-28032003000100012
network_acronym_str IBEPEGE-1
network_name_str Arquivos de gastroenterologia (Online)
repository_id_str
spelling The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapyHelicobacter infectionsPeptic ulcerHelicobacter pyloriAnti-ulcer agentsBenzimidazolesSulfoxidesBACKGROUND: Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. AIM: We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. METHODS: Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. RESULTS: One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/15 (67%)]. There were six (15%) mild adverse events reports. CONCLUSIONS: A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE. 2003-03-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000100012Arquivos de Gastroenterologia v.40 n.1 2003reponame:Arquivos de gastroenterologia (Online)instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiainstacron:IBEPEGE10.1590/S0004-28032003000100012info:eu-repo/semantics/openAccessEisig,Jaime NatanAndré,Suraia BoaventuraSilva,Fernando MarcuzHashimoto,CláudioMoraes-Filho,Joaquim Prado PintoLaudanna,Antonio Atilioeng2003-10-06T00:00:00Zoai:scielo:S0004-28032003000100012Revistahttp://www.scielo.br/aghttps://old.scielo.br/oai/scielo-oai.php||secretariaarqgastr@hospitaligesp.com.br1678-42190004-2803opendoar:2003-10-06T00:00Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiafalse
dc.title.none.fl_str_mv The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
title The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
spellingShingle The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
Eisig,Jaime Natan
Helicobacter infections
Peptic ulcer
Helicobacter pylori
Anti-ulcer agents
Benzimidazoles
Sulfoxides
title_short The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
title_full The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
title_fullStr The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
title_full_unstemmed The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
title_sort The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy
author Eisig,Jaime Natan
author_facet Eisig,Jaime Natan
André,Suraia Boaventura
Silva,Fernando Marcuz
Hashimoto,Cláudio
Moraes-Filho,Joaquim Prado Pinto
Laudanna,Antonio Atilio
author_role author
author2 André,Suraia Boaventura
Silva,Fernando Marcuz
Hashimoto,Cláudio
Moraes-Filho,Joaquim Prado Pinto
Laudanna,Antonio Atilio
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Eisig,Jaime Natan
André,Suraia Boaventura
Silva,Fernando Marcuz
Hashimoto,Cláudio
Moraes-Filho,Joaquim Prado Pinto
Laudanna,Antonio Atilio
dc.subject.por.fl_str_mv Helicobacter infections
Peptic ulcer
Helicobacter pylori
Anti-ulcer agents
Benzimidazoles
Sulfoxides
topic Helicobacter infections
Peptic ulcer
Helicobacter pylori
Anti-ulcer agents
Benzimidazoles
Sulfoxides
description BACKGROUND: Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. AIM: We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. METHODS: Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. RESULTS: One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/15 (67%)]. There were six (15%) mild adverse events reports. CONCLUSIONS: A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.
publishDate 2003
dc.date.none.fl_str_mv 2003-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000100012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032003000100012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-28032003000100012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
dc.source.none.fl_str_mv Arquivos de Gastroenterologia v.40 n.1 2003
reponame:Arquivos de gastroenterologia (Online)
instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
instname_str Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron_str IBEPEGE
institution IBEPEGE
reponame_str Arquivos de gastroenterologia (Online)
collection Arquivos de gastroenterologia (Online)
repository.name.fl_str_mv Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
repository.mail.fl_str_mv ||secretariaarqgastr@hospitaligesp.com.br
_version_ 1754193342895226880